cefotaxime

Cefotaxime is an inhibitor of penicillin binding protein.

3-Desacetyl Cefotaxime lactone, the active metabolite of Cefotaxime, is derived from its sodium salt form, which is recognized as a third-generation cephalosporin antibiotic.

Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium (Cefotaxim sodium salt) is marketed under various trade names including Claforan (Sanofi-Aventis).

Cefotaxime-D3 is the deuterium-labeled form of Cefotaxime. Cefotaxime (T7733) is a cephalosporin stable against β-lactamase, classified as a third-generation cephalosporin antibiotic. It exhibits broad-spectrum antibacterial activity against a variety of Gram-positive and Gram-negative bacteria.

Cefotaxime (Standard) is the standard substance of Cefotaxime, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Cefotaxime is an inhibitor of penicillin binding protein.

Cefotaxime sodium (Standard) is the standard substance of Cefotaxime sodium, and it is applicable for quantitative analysis, quality control, and related research in biochemical experiments. Cefotaxime is a third-generation cephalosporin antibiotic. Like other third-generation cephalosporins, it has broad spectrum activity against Gram positive and Gram negative bacteria. In most cases, it is considered to be equivalent to ceftriaxone in terms of safety and efficacy. Cefotaxime sodium (Cefotaxim sodium salt) is marketed under various trade names including Claforan (Sanofi-Aventis).

Cefotaxime-[13C,D3] (Standard) is a reference standard of Cefotaxime-[13C,D3] intended for quantitative analysis, quality control, and related biochemical research applications.

Desacetylcefotaxime is an active metabolite of the cephalosporin antibiotic cefotaxime .1It is active against 60 clinical isolates derived from patients with meningitis, includingH. influenzae,S. pneumoniae,S. agalactiae, andN. meningitidis(MIC90s = 0.008-0.12 μg/ml). 1.Jones, R.N.Cefotaxime and desacetylcefotaxime antimicrobial interactions. The clinical relevance of enhanced activity: A reviewDiagn. Microbiol. Infect. Dis.22(1-2)19-33(1995)

Desacetylcefotaxime, an in vivo metabolite of Cefotaxime (CTX), exhibits noteworthy in vitro antimicrobial efficacy, akin to its parent compound, against a broad spectrum of aerobic and anaerobic bacteria [1].

Cefetamet is a third-generation cephalosporin and broad-spectrum antibiotic. It inhibits bacterial cell wall synthesis via PBP binding, effective against various Gram-negative pathogens.

Ceftizoxime, a third-generation cephalosporin effective against Gram-negative and Gram-positive bacteria, binds penicillin-binding proteins (PBPs) to inhibit the bacterial cell wall synthesis. It rather resembles cefotaxime in its properties but is not su

Desacetyl cefapirin is an active metabolite of the cephalosporin antibiotic cefapirin .1 Desacetyl cefapirin is active against E. coli, K. pneumoniae, P. mirabilis, and S. aureus with MIC values of 120, 24, 34, and 0.42 μg/ml, respectively.References1. Jones, R.N., and Packer, R.R. Cefotaxime, cephalothin, and cephapirin: Antimicrobial activity and synergy studies of cephalosporins with significant in vivo desacetyl metabolite concentrations. Diagn. Microbiol. Infect. Dis. 2(1), 65-68 (1984). Desacetyl cefapirin is an active metabolite of the cephalosporin antibiotic cefapirin .1 Desacetyl cefapirin is active against E. coli, K. pneumoniae, P. mirabilis, and S. aureus with MIC values of 120, 24, 34, and 0.42 μg/ml, respectively. References1. Jones, R.N., and Packer, R.R. Cefotaxime, cephalothin, and cephapirin: Antimicrobial activity and synergy studies of cephalosporins with significant in vivo desacetyl metabolite concentrations. Diagn. Microbiol. Infect. Dis. 2(1), 65-68 (1984).

KPC-2-IN-2 (Compound 6c) is a potent Klebsiella pneumoniae carbapenemase (KPC-2) inhibitor with a Ki of 0.038 μM and can enhance the activity of cefotaxime in E. coli expressing KPC-2 [1].

KPC-2-IN-1, a boronic acid derivative, serves as an effective KPC-2 inhibitor with a K i of 0.032 μM, augmenting cefotaxime's efficacy against KPC-2 expressing E. coli. It demonstrates good tolerance in human HEK-293 cells, rendering it valuable for researching E. coli's resistance to β-lactam antibiotics [1] [2].